Ablacon Secures $21.5M Series A Funding to Advance AI-Powered Electrographic Flow Mapping System for Atrial Fibrillation Treatment

VCBeat (WeChat ID: vcbeat) has learned that medical technology company Ablacon recently announced the completion of a $21.5 million Series A financing round, led by Ajax Health. The company will utilize these funds to advance the development and clinical trials of its core electrocardiographic mapping system technology, as well as to conduct further product testing.

Following the completion of the financing, Duke Rohlen, CEO of Ajax Health, will join Ablacon as Chairman and Chief Executive Officer. Peter Ruppersberg, founder and former CEO of Ablacon, will continue to serve as the company’s President and Chief Scientific Officer.

Headquartered in Colorado, USA, Ablacon is a medical technology company with offices in Lausanne, Switzerland, and Munich, Germany. The company is dedicated to developing electrocardiographic mapping systems that provide rapid, precise, and effective guidance for physicians in the treatment of atrial fibrillation. The system’s core technology, known as Electrographic Flow, leverages advanced machine algorithms and artificial intelligence (AI) to enable real-time, clear visualization of intracardiac electrical signals, thereby generating a visualized electrocardiogram. By analyzing this electrocardiogram to determine the etiology and progression of atrial fibrillation, the system guides physicians in performing targeted catheter ablation procedures.

Ablacon’s electrocardiographic mapping system has not yet received clinical approval, but its Electrographic Flow technology obtained CE certification in 2018, indicating that the system complies with EU medical device standards. The company is seeking to enter the AI medical device market, which is projected to reach a value of $36.1 billion by 2025.

Vivek Reddy, Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City, stated, “The electrocardiographic mapping system developed by Ablacon holds significant promise. Early clinical trials have demonstrated that this system can substantially enhance physicians’ ability to treat atrial fibrillation. The company’s innovative approach combines medical technology with machine intelligence, leveraging machine algorithms and artificial intelligence to analyze electrical signals within the heart.”

Atrial fibrillation is the most common type of cardiac arrhythmia, characterized by symptoms such as palpitations, chest tightness, and heart palpitations. It is projected that by 2060, more than 30 million people in the United States and Europe will be affected by this condition. The electrocardiographic (ECG) hallmark of atrial fibrillation is the absence of P waves, which are replaced by continuous, irregular fibrillatory waves with varying morphology, amplitude, and inconsistent time intervals. Currently, catheter-based radiofrequency ablation can provide a curative treatment for this disease.

Ajax Health, founded in 2017 and headquartered in California, USA, is a healthcare enterprise incubator primarily focused on electrophysiology-related medical technologies. Led by Duke Rohlen, a veteran in the medical technology sector, the company is dedicated to advancing medical innovation and improving quality of life by providing funding, technical support, and other resources to medical technology and medical device companies.

(Compiled by Jiao Yanli)